AQP4-Selective Peptides for Aquaporin Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs with modulating activity on aquaporins, particularly aquaporin 4 (AQP4), have adverse effects due to interactions with other pharmacological targets, and there is a need for more specific AQP modulators that do not affect carbonic anhydrase, serotonin receptors, acetylcholine receptors, or dopamine receptors.
Innovation Solution
Development of peptides with a molecular weight of less than 2000, specifically designed to modulate or inhibit AQP4 with negligible effects on other receptors, using a peptide structure that includes organic groups, azido, and alkyne moieties, and potentially forming covalent or non-covalent links, to achieve high binding affinity and selectivity for AQP4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known compounds and drugs are used to modulate aquaporins, then aquaporin modulating activity is achieved, but adverse effects occur due to interactions with other pharmacological targets
Solution Approach 1:
The patent applies local quality by designing peptides with specific local structural features (formula I with particular X, Y, Z, R1, R2, R5 groups) that confer selective binding to AQP4. The molecular structure incorporates specific functional groups and spatial arrangements that target AQP4's unique binding site, ensuring localized interaction without affecting other receptors.
Solution Approach 2:
The patent employs parameter changes by optimizing the peptide's molecular weight (less than 2000 Da) and chemical structure (specific X, Y, Z, R1, R2, R5 parameters in formula I) to achieve high binding affinity (less than 200 nanomolar) for AQP4. These parameter optimizations enable selective AQP4 modulation while minimizing off-target effects on other pharmacological receptors.
2Measurement precision
If high binding affinity for AQP4 is achieved, then selectivity is improved, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the peptide structure into distinct functional segments defined by formula I, where each parameter (X, Y, Z, R1, R2, R5) represents a specific structural segment with defined chemical properties. This modular approach allows systematic optimization of binding affinity while maintaining structural clarity and synthesis feasibility.
Solution Approach 2:
The patent uses composite materials by combining different chemical groups (organic groups, azido, and alkyne moieties) within the peptide structure to create a composite molecule with enhanced AQP4 binding affinity. The composite structure integrates multiple functional elements that work synergistically to achieve high selectivity without excessive molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively modulate or inhibit AQP4 with high specificity, reducing side effects by minimizing interaction with other targets, and exhibit binding affinities of less than 200 nanomolar, thereby addressing the need for targeted AQP4 modulation.
Implementation Method 1
The peptides effectively modulate or inhibit AQP4 with high specificity, exhibiting binding affinities of less than 200 nanomolar
Data Source
AI summary
A peptide comprising a unit of formula (I) and having a molecular weight of less than 2000 wherein each X is independently an organic group, e.g. a C1-6 alkyl or C1-6 alkenyl group, preferably —CH2—CH═CH2, or the two X groups taken together can form a covalent or non-covalent link between the two O groups, preferably a C1-10 saturated or unsaturated carbon chain optionally interrupted by one or more heteroatoms selected from O, S, N, P, or Si, especially a C3-10 carbon chain or one X represents an azido group and the other an C2-6-alkynyl group; both Z's are the same and are O or S; each Y is independently C, CH, CH2, N or NH; R1 is H or C1-6 alkyl; R2 is H or C1-6 alkyl; R5 is a C1-6 alkyl group, preferably isopropyl; or a salt, ester or prodrug thereof.